Literature DB >> 20566770

In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.

Jesús Guinea1, Sandra Recio, Pilar Escribano, Teresa Peláez, Beatriz Gama, Emilio Bouza.   

Abstract

We compared the in vitro activities of isavuconazole, posaconazole, voriconazole, and fluconazole against Dipodascus capitatus (n = 21), Saccharomyces cerevisiae (n = 20), Rhodotorula mucilaginosa (n = 18), and Trichosporon spp. (n = 15). The MIC(50)s, MIC(90)s, and MIC ranges (in microg/ml) obtained using the CLSI M27-A3 procedure were as follows: isavuconazole, 0.125, 0.5, and < or = 0.015 to 2; posaconazole, 0.5, 2, and < or = 0.015 to > 16; voriconazole, 0.125, 2, and < or = 0.015 to 8; and fluconazole, 4, > 128, and < or = 0.125 to > 128. Isavuconazole showed potent activity against the isolates studied.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20566770      PMCID： PMC2935032          DOI： 10.1128/AAC.00685-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro antifungal susceptibilities of Trichosporon species.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 2.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 3.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

4.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.

Authors:  J B Pfaller; S A Messer; R J Hollis; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

6.  Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.

Authors:  Jesús Guinea; Teresa Peláez; Luis Alcalá; Emilio Bouza
Journal:  Diagn Microbiol Infect Dis       Date:  2006-12-01       Impact factor: 2.803

7.  [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].

Authors:  Banu Sancak; Sehnaz Alp; Gülşen Hasçelik; Sevtap Arikan
Journal:  Mikrobiyol Bul       Date:  2009-04       Impact factor: 0.622

8.  In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors:  Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

9.  Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Annette W Fothergill; Nathan P Wiederhold; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
View more
  10 in total

1.  Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Rachel R Dietrich; Ronald N Jones; Michael A Pfaller
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

2.  The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.

Authors:  Marçal Mariné; Vinicius Leite Pedro Bom; Patricia Alves de Castro; Lizziane Kretli Winkelstroter; Leandra Naira Ramalho; Neil Andrew Brown; Gustavo Henrique Goldman
Journal:  Virulence       Date:  2015-03-09       Impact factor: 5.882

3.  Efficacy of Posaconazole in a Murine Model of Systemic Infection by Saprochaete capitata.

Authors:  Pamela Thomson; Josep Guarro; Emilio Mayayo; Javier Capilla
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

Review 5.  New Perspectives on Antimicrobial Agents: Isavuconazole.

Authors:  James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2022-08-15       Impact factor: 5.938

6.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

7.  Molecular identification, antifungal susceptibility profile, and biofilm formation of clinical and environmental Rhodotorula species isolates.

Authors:  Jorge Meneses Nunes; Fernando César Bizerra; Renata Carmona E Ferreira; Arnaldo Lopes Colombo
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 8.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.

Authors:  Diego R Falci; Alessandro C Pasqualotto
Journal:  Infect Drug Resist       Date:  2013-10-22       Impact factor: 4.003

Review 9.  Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

Authors:  Jeffrey D Jenks; Helmut Jf Salzer; Juergen Prattes; Robert Krause; Dieter Buchheidt; Martin Hoenigl
Journal:  Drug Des Devel Ther       Date:  2018-04-30       Impact factor: 4.162

10.  Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin.

Authors:  Salvatore Perrone; Chiara Lisi; Elettra Ortu La Barbera; Cristina Luise; Miriam Lichtner; Corrado Girmenia; Giuseppe Cimino
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-05-01       Impact factor: 2.576
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.